# Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

> **NCT05656248** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 25 (actual)

## Conditions studied

- Myeloid Neoplasm

## Interventions

- **DRUG:** CPX-351
- **DRUG:** MHA
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT05656248
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-17
- **Primary completion:** 2025-08-28
- **Final completion:** 2028-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05656248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05656248, "Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05656248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*